1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6552221568FDBA001852584170039933E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/552221568FDBA001852584170039933E!OpenDocument
18
19OpenDocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Patient Advocacy Groups

Document Excerpt: Patient Advocacy: Optimizing Advocacy Partnerships to Improve Access & Boost Patient Voice

DB Image

Excerpt in Cart

ID: MD-661


Features:

21 Info Graphics

13 Data Graphics

250+ Metrics

8 Narratives


Pages/Slides: 4


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5561 "Patient Advocacy: Optimizing Advocacy Partnerships to Improve Access and Boost Patient Voice."

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.